Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects

British Journal of Clinical Pharmacology

Volumn 63, Issue 5, 2007, Pages 614-617

  Zhao, Qian ^a   Jiang, Ji ^a   Li, XiaoMing ^a   Lu, Zhihong ^b   Hu, Pei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b UCB PHARMA   (Belgium)

Author keywords

Chinese subjects; Epilepsy; Keppra; Levetiracetam; Pharmacokinetics; ucb L059

Indexed keywords

ETIRACETAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; EVALUATION; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; PIRACETAM;

EID: 34247355590     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02782.x     Document Type: Article

References (11)

1. Glauser TA, Pellock JM, Bebin EM, Fountain NB, Ritter FJ, Jensen CM, Shields WD. Efficacy and safety of levetiracetam in children with partial seizures. Epilepsia 2002 43 : 518 24.
2. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/day in patients with refractory partial seizures. Epilepsia 2000 41 : 1276 83.
3. Grant R, Shorvon SD. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy Res 2000 42 : 89 95.
4. French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam. Epilepsy Res 2001 4 : 77 90.
5. Beran RG, Berkovic SF, Black AB, Danta G, Hiersemenzel R, Schapel GJ, Vajda FJ. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures. Epilepsy Res 2005 63 : 1 9.
6. Harden C. Safety profile of levetiracetam. Epilepsia 2001 42 : 36 9.
7. Benedetti MS, Whomsley R, Nicolas JM, Young C, Baltes E. Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur J Clin Pharmacol 2003 59 : 621 30.
8. Doheny HC, Ratnaraj N, Whittington MA, Jefferys JG, Patsalos PN. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam in the rat. Epilepsy Res 1999 34 : 161 8.
9. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004 43 : 707 24.
10. Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia 2001 42 : 24 7.
11. Patsalos PN. Pharmacokinetic profile of levetiracetam. Pharmacol Ther 2000 85 : 77 85.